Tasigna + Gleevec
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
All Indications for Glivec/Gleevec and Tasigna
Conditions
All Indications for Glivec/Gleevec and Tasigna
Trial Timeline
Jan 1, 2011 → Mar 1, 2015
NCT ID
NCT01289054About Tasigna + Gleevec
Tasigna + Gleevec is a pre-clinical stage product being developed by Novartis for All Indications for Glivec/Gleevec and Tasigna. The current trial status is completed. This product is registered under clinical trial identifier NCT01289054. Target conditions include All Indications for Glivec/Gleevec and Tasigna.
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01289054 | Pre-clinical | Completed |
Competing Products
2 competing products in All Indications for Glivec/Gleevec and Tasigna
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody | Bristol Myers Squibb | Phase 1 | 29 |
| Dasatinib | Bristol Myers Squibb | Phase 2 | 35 |